A note to the community
On June 12, 2022, Day One announced positive initial data from the first subset of participants in our ongoing pivotal Phase 2 FIREFLY-1 trial of tovorafenib (DAY101) in patients with relapsed pediatric low-grade glioma, or pLGG. Please see our press release and corporate presentation for more details.
On behalf of everyone at Day One, we thank the patients who have participated in the FIREFLY-1 study and their families, without whom this advancement toward a potential new targeted therapy for pLGG would not be possible.
We also thank the pediatric cancer patient advocacy community for your partnership and support as we move forward in developing potential new therapies for children with cancer.